Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth policy | OpenPaye…
    Ask Trek AI about this page
    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization (Medicare - Wellcare by Fidelis Care)

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization and review requirements by Evolent for oncology medications and supportive agents (medical and pharmacy benefit) for Fidelis Care Medicare - Wellcare participating providers; lists drugs/HCPCS/J-codes requiring review and out-of-scope items.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization (Medicare - Wellcare)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent for review prior to dispensing or administering listed agents; omissions may result in denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+listed HCPCS/J-codes and Q-codes requiring review
    Out-of-scope listcategories not to submit to Evolent
    Biosimilar preferencespreferred biosimilars for certain oncology agents
    2026-04-01Wellcare additions effective

    Coverage Criteria & Scope

    Prior authorization / review requirement

    Covered when review is performed by Evolent for listed drugs prior to dispensing or administration.

    Primary requirement: Provider must submit the entire oncology regimen to Evolent and obtain review prior to dispensing at a pharmacy or administering in a physician office, outpatient hospital, or ambulatory setting for members of all ages.

    Requests can be submitted via Evolent's web portal (my.newcenturyhealth.com) or by calling 1-888-999-7713, option 1. If non-participating provider, submit request to the plan via fax 1-844-235-5090.

    Do NOT submit the following to Evolent; these items are out of scope for prior authorization review: Antibiotics; Bone marrow, stem cell transplants and CAR‑T cell therapy; Controlled substances (e.g., morphine); Equipment requests (infusion pumps); Genetic laboratory testing and laboratory services; Hemophilia drugs; Inpatient drug requests; Inpatient radiation and chemotherapy treatments; Iron preparations; Radiopharmaceuticals; Surgeries/surgical procedures; Sickle cell diagnoses and therapies; and Immune globulins.

    HCPCS / J / Q Codes Requiring Review

    Selected HCPCS/J codes (excerpt)HCPCS
    C9293GLUCARPIDASE
    J0894
    J0185DECITABINE INJ / APREPITANT INJ (appears multiple)
    J0207LUSPATERCEPT-AAMT / AMIFOSTINE INJ (appears multiple)
    HCPCS/J codes (additional list)HCPCS
    J1448TRILACICLIB INJ
    J2506PEGFILGRASTIM (ON-BODY INJECTOR) / PEGFILGRASTIM INJECTION
    J9034BENDAMUSTINE (RAPID INFUSION BENDEKA)
    J9312RITUXIMAB AND HYALURONIDASE HUMAN
    J9317PERTUZUMAB/TRASTUZUMAB/HYAL INJ
    J9271PEMBROLIZUMAB
    J9349TAFASITAMAB-CXIX INJ
    J9355TRA STUZUMAB INJ
    Q-codes (select)HCPCS
    Q2043SIPULEUCEL-T AUTO CD5+
    Q2050LIPOSOMAL DOXORUBICIN
    Q5101FILGRASTIM-SNDZ
    Q5116RITUXIMAB-ABBS
    Pharmacy benefit oral agents (J-/J8999 group)HCPCS|mixed
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL
    J8999Multiple oral oncology agents listed (generic/oral medications) — extensive list

    What Providers Must Do

    Prior Authorization

    Prior Authorization Required

    Oncology medications and supportive agents listed by HCPCS/J/Q codes require prior review by Evolent before being dispensed or administered for members of all ages. This includes administration in physician offices, outpatient hospitals, ambulatory settings, and dispensing at pharmacies. Clinical trial agents may also be submitted to Evolent for review.

    • Prior authorization required for listed oncology agents and supportive drugs (HCPCS/J/Q codes) — submit to Evolent before dispensing/administration
    • Requests may be submitted via Evolent's web portal (my.newcenturyhealth.com) or by phone: 1-888-999-7713, option 1
    • Non-participating providers should submit requests to the plan by fax: 1-844-235-5090
    Denial Risk

    Submit Entire Oncology Regimen

    Submit the entire oncology regimen to Evolent for review, even if individual agents in the regimen are not subject to prior authorization. Omitting drugs or components of the regimen when submitting may result in a denial of coverage.

    Where Prior Review Applies

    Prior Authorization

    Prior review required for pharmacy, office, infusion center, and hospital outpatient

    Prior review by Evolent is required before dispensing at a pharmacy or administration in physician office, infusion/ambulatory center, or hospital outpatient setting.

    Biosimilar Preferences and Notes

    Billing Rule

    Erythropoiesis‑stimulating agents — Retacrit preferred (medical); Procrit (pharmacy)

    Erythropoiesis-stimulating agents: the policy lists Retacrit as the preferred medical‑benefit agent (use Epogen if Retacrit is unavailable due to shortage); Procrit is listed for the pharmacy benefit.

    Billing Rule

    Trastuzumab — Trazimera preferred (medical); Herceptin and biosimilars (pharmacy)

    Trastuzumab biosimilar preference: Trazimera is the preferred medical‑benefit trastuzumab; pharmacy benefit options include Herceptin and the listed biosimilars (Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera).

    Billing Rule

    Bevacizumab — Mvasi/Zirabev preferred (medical); Avastin/Mvasi/Zirabev (pharmacy)

    Step Therapy / Regimen Preference

    Preferred biosimilarBenefitProvider action
    Retacrit (if unavailable due to shortage: Epogen)Medical benefitConsider and send to Evolent for review as part of the regimen submission
    ProcritPharmacy benefitConsider and send to Evolent for review as part of the regimen submission
    TrazimeraMedical benefitConsider and send to Evolent for review as part of the regimen submission
    Herceptin; Herceptin Hylecta; Herzuma; Kanjinti; Ogivri; Ontruzant; TrazimeraPharmacy benefitConsider and send to Evolent for review as part of the regimen submission
    Mvasi; ZirabevMedical benefitConsider and send to Evolent for review as part of the regimen submission
    Avastin; Mvasi; ZirabevPharmacy benefitConsider and send to Evolent for review as part of the regimen submission
    ZarxioMedical & Pharmacy benefitConsider and send to Evolent for review as part of the regimen submission
    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization (Medicare - Wellcare)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent for review prior to dispensing or administering listed agents; omissions may result in denial.
    SourceLink
    On This Page
    Coverage Criteria & ScopeHCPCS / J / Q Codes Requiring ReviewWhat Providers Must DoWhere Prior Review AppliesBiosimilar Preferences and NotesStep Therapy / Regimen Preference
    • Always include all agents, schedules, and supportive medications that are part of the patient’s planned regimen
    • Do not submit only select drugs — partial submissions increase risk of denial
    Note

    Biosimilar Preference Notification

    Fidelis Care has identified preferred biosimilar agents for oncology-related indications. Providers should note these preferences and still send the selected (including preferred biosimilars) agent(s) to Evolent for review.

    • Erythropoiesis-stimulating agents: Medical benefit preferred Retacrit (if unavailable due to shortage: Epogen); Pharmacy benefit: Procrit
    • Trastuzumab: Medical benefit preferred Trazimera; Pharmacy benefit options include Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera
    • Bevacizumab: Medical benefit preferred Mvasi, Zirabev; Pharmacy benefit options include Avastin, Mvasi, Zirabev
    • Hematopoietic agents: Medical & Pharmacy benefit preferred Zarxio
    • Even when prescribing a preferred biosimilar, submit the agent and regimen to Evolent for authorization

    Bevacizumab biosimilar preference: Mvasi and Zirabev are preferred for the medical benefit; pharmacy benefit options include Avastin, Mvasi, and Zirabev.